Health outcomes of bedaquiline in the treatment of multidrug-resistant tuberculosis in selected high burden countries

BMC Health Services Research

Volumn 17, Issue 1, 2017, Pages

  Lu, Xiaoyan ^a   Smare, Caitlin ^b   Kambili, Chrispin ^c   El Khoury, Antoine C ^d   Wolfson, Lara J ^a  

^a JANSSEN RESEARCH FOUNDATION   (Belgium)

^b PAREXEL INTERNATIONAL   (United States)

^c JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^d JOHNSON AND JOHNSON   (United States)

Author keywords

Cost effectiveness threshold; DALY

Indexed keywords

BEDAQUILINE; QUINOLINE DERIVATIVE; TUBERCULOSTATIC AGENT;

CHINA; CLINICAL PROTOCOL; COST BENEFIT ANALYSIS; ECONOMICS; ESTONIA; HEALTH CARE COST; HUMAN; INDIA; MARKOV CHAIN; OUTCOME ASSESSMENT; PERU; PHILIPPINES; QUALITY ADJUSTED LIFE YEAR; RUSSIAN FEDERATION; SOUTH AFRICA; TRENDS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANTITUBERCULAR AGENTS; CHINA; CLINICAL PROTOCOLS; COST-BENEFIT ANALYSIS; DIARYLQUINOLINES; ESTONIA; HEALTH CARE COSTS; HUMANS; INDIA; MARKOV CHAINS; OUTCOME ASSESSMENT (HEALTH CARE); PERU; PHILIPPINES; QUALITY-ADJUSTED LIFE YEARS; RUSSIA; SOUTH AFRICA; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 85010952269     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/s12913-016-1931-3     Document Type: Article

References (43)

1. CDC. Notice to readers: revised definition of extensively drug-resistant tuberculosis. Morb Mortal Wkly Rep. 2006;55(43):1176.
2. WHO. Global Tuberculosis Report. 2014.
3. WHO. Guidelines for the programmatic management of drug-resistant tuberculosis - Emergency update. 2008.
4. Janssen. Sirturo: Prescribing information. 2012.
5. Janssen. Sirturo: Summary of product characteristics. 2015.
6. WHO. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis - Interim policy guidance. 2013.
7. WHO, Vassall A. Cost-effectiveness of introducing Bedaquiline in MDR-TB regimens - An exploratory analysis. 2013 Jan 26.
8. Fitzpatrick C, Floyd K. A systematic review of the cost and cost effectiveness of treatment for multidrug-resistant tuberculosis. Pharmacoeconomics. 2012;30(1):63-80.
9. Wolfson LJ, Walker A, Hettle R, Lu X, Kambili C, Murungi A, et al. Cost-Effectiveness of Adding Bedaquiline to Drug Regimens for the Treatment of Multidrug-Resistant Tuberculosis in the UK. PLoS ONE. 2015;10(3):e0120763.
10. Murray CJ. Qualifying the burden of disease: the technical basis for disability-adjusted life years. Bull World Health Organ. 1994;72:429-45.
11. NICE. Measuring effectiveness and cost-effectiveness: the QALY. https://www.nice.org.uk/glossary?letter=q. Accessed Dec 2016. 2010. Ref Type: Online Source.
12. Diacon AH, Pym A, Grobusch MP, Rios JM de l, Gotuzzo E, Vasilyeva I, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med. 2014;371(8):723-32.
13. FDA. Treatment of patients with MDR-TB-TMC207 (bedaquiline) - Anti-Infective Drugs Advisory Committee Meeting. 2012 Nov 28.
14. WHO. Data on diagnosis, notification and treatment outcome of MDR-TB by region or country, 2010. https://extranet.who.int/sree/Reports?op=vs&path=/WHO-HQ-Reports/G2/PROD/EXT/MDRTB-Indicators-charts. Accessed June 2014. 2014. Ref Type: Online Source.
15. Health Protection Agency. Tuberculosis in the UK. 2013.
16. Salomon JA, Vos T, Hogan DR, Gagnon M, Naghavi M, Mokdad A, et al. Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2129-43.
17. ONS. Office for the National Statistics Life Tables 2009-2011, England and Wales. http://www.ons.gov.uk/ons/rel/lifetables/interim-life-tables/2009-2011/rft-england-and-wales.xls. Accessed Dec 2013. 2013. Ref Type: Online Source.
18. Russian State. Register of marginal cost prices. http://grls.rosminzdrav.ru/pricelims.aspx. Accessed June 2014. 2014. Ref Type: Online Source.
19. Russian State. Russian monitoring costs pricelist. http://critub.ru/. Accessed Dec 2016. 2013. Ref Type: Online Source.
20. EHIF. Estonian Health Insurance Fund. https://www.haigekassa.ee/en. Accessed June 2014. 2014. Ref Type: Online Source.
21. EsSalud. Peru social health insurance. http://www.essalud.gob.pe/. Accessed June 2014. 2014. Ref Type: Online Source.
22. Peru State. Peru Electronic System of State Procurement. http://www2.seace.gob.pe/?scriptdo=PKU-CONSULTA-TOP.doview&-CALIFICADOR-=PORTLET.1.117.0.21.81&-REGIONID-=1&-PORTLETID-=117&-ORDERID-=0&-PAGEID-=21&-CONTENTID-=81&-USERID-=%3C%21 - USERID - %3E&-PRIVILEGEID-=1. Accessed June 2014. 2014. Ref Type: Online Source.
23. Chinese State. China Price information network. http://www.chinaprice.com.cn/fgw/chinaprice/free/index.htm. Accessed June 2014. 2014. Ref Type: Online Source.
24. WHO. WHO-CHOICE costs for 2008, inflated to 2013. http://www.who.int/choice/cost-effectiveness/inputs/health-service/en/. Accessed June 2014. 2014. Ref Type: Online Source.
25. WHO. Global Drug Facility - List of products available. http://www.stoptb.org/gdf/drugsupply/catalogue.asp. Accessed June 2014. 2014. Ref Type: Online Source.
26. Pooran A, Pieterson E, Davids M, Theron G, Dheda K. What is the cost of diagnosis and management of drug resistant tuberculosis in South Africa? PLoS ONE. 2013;8(1):e54587.
27. Zhang X, Nievera M, Carlos J, Lucero M, Bibera G, Atienza M, et al. Cost-effectiveness analysis of pneumococcal vaccination with pneumococcal polysaccharide NTHi protein D conjugate vaccine in the Philippines. Value Health Reg Issues. 2014;3:156-66.
28. Gupta SK. Proposed pharmacoeconomics guidelines for India (PEG-I). 2013.
29. ISPOR. Pharmacoeconomic guidelines around the world. http://www.ispor.org/peguidelines/index.asp. Accessed Jan 2015. 2015. 30-1-2015. Ref Type: Online Source.
30. WHO. WHO-CHOICE Cost effectiveness thresholds. http://www.who.int/choice/costs/CER-levels/en/. Accessed June 2014. 2014. Ref Type: Online Source.
31. WHO. Global Tuberculosis Report. 2013.
32. Joint Tuberculosis Committee of the British Thoracic Society. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Joint tuberculosis committee of the British thoracic society. Thorax. 1998;53(7):536-48.
33. WHO. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. 2014.
34. Liu CH, Li L, Chen Z, Wang Q, Hu YL, Zhu B, et al. Characteristics and treatment outcomes of patients with MDR and XDR tuberculosis in a TB referral hospital in Beijing: a 13-year experience. PLoS ONE. 2011;6(4):e19399.
35. Tiemersma EW, van der Werf MJ, Borgdorff MW, Williams BG, Nagelkerke NJ. Natural history of tuberculosis: duration and fatality of untreated pulmonary tuberculosis in HIV negative patients: a systematic review. PLoS ONE. 2011;6(4):e17601.
36. UK Department of Health. National Health System: Reference costs 2011-2012. 2012
37. Patient India. Indian tender price. http://patientindia.com/. Accessed June 2014. 2014. Ref Type: Online Source.
38. Lu C, Liu Q, Sarma A, Fitzpatrick C, Falzon D, Mitnick CD. A systematic review of reported cost for smear and culture tests during multidrug-resistant tuberculosis treatment. PLoS ONE. 2013;8(2):e56074.
39. Muniyandi M, Rajeswari R, Balasubramanian R. Estimating provider cost for treating patients with tuberculosis under Revised National Tuberculosis Control Programme (RNTCP). Indian J Tuberc. 2006;53:12-7.
40. Jit M, Stagg HR, Aldridge RW, White PJ, Abubakar I. Dedicated outreach service for hard to reach patients with tuberculosis in London: observational study and economic evaluation. BMJ. 2011;343:d5376.
41. Kind P, Hardman G, Macran S. UK population norms for EQ-5D. 1999
42. Guglielmetti L, Le DD, Jachym M, Henry B, Martin D, Caumes E, Veziris N, Metivier N, Robert J. Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort. Clin Infect Dis. 2015;60(2):188-94.
43. Ndjeka N, Conradie F, Hughes J, Schnipel K, Cox H, Bantubani N, Ferreira H, Maartens G, Master I, Meintjes G, Padanilam X, Pym A, Siwendu S, Variava E. Safe and effective bedaquiline treatment of drug-resistant tuberculosis (DR-TB) within the National Bedaquiline Clinical Access Programme in South Africa. Barcelona, Spain: 45th Union World Conference on Lung Health; 2014.